New Insights in Tumor-Infiltrating Lymphocytes

Dear Colleagues,

The limited success of the many promising therapeutic approaches attempted renders the treatment of many solid cancers one of the most urgent unmet needs in oncology.

Immunotherapy and cell therapy can represent an important option; however, the immune suppressive microenvironment can influence their efficacy.

We are living in an era where single-cell and multi-omics technologies are holding the potential to revolutionize the way to characterize the immune cells within the microenvironment and study their diversity, clonal distribution, pathways, and crosstalk. Tumor-infiltrating lymphocytes (TILs) are deserving of particular attention because they can be used as direct treatment mediators exerting an effective antitumor activity with low side effects per se. However, within the microenvironment, TILs engaged in tumor cell elimination become dysfunctional.

In light of this very important clinical objective, we need your innovative and original contribution to capture new insights in:

• Prognostic significance of TILs in solid cancers;
• Dysfunction in the relationship with the interaction with the microenvironment;
• Potential therapeutic reprogrammability;
• Identification of accessible markers to predict the functionality of TILs and/or their reprogramming.

We believe that this emerging area can greatly impact translational research of the immune system.

Dr. Serena Pellegatta
Dr. Natalia Di Ianni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.